Genomic Health, Inc. (NASDAQ:GHDX) has earned a consensus rating of “Hold” from the thirteen ratings firms that are presently covering the firm, Marketbeat reports. Ten analysts have rated the stock with a hold recommendation, one has given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $62.17.
GHDX has been the topic of a number of research analyst reports. ValuEngine raised Genomic Health from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 13th. Needham & Company LLC reaffirmed a “strong-buy” rating and set a $97.00 price target (up from $86.00) on shares of Genomic Health in a report on Thursday, February 21st. Piper Jaffray Companies upped their price target on Genomic Health to $86.00 and gave the company a “neutral” rating in a report on Thursday, February 21st. BidaskClub downgraded Genomic Health from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 28th. Finally, Zacks Investment Research downgraded Genomic Health from a “buy” rating to a “hold” rating in a report on Tuesday, April 23rd.
In other Genomic Health news, insider Steven Shak sold 50,000 shares of the stock in a transaction dated Thursday, February 28th. The stock was sold at an average price of $76.50, for a total value of $3,825,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Frederic Pla sold 9,700 shares of the stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $83.16, for a total value of $806,652.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,486,816 shares of company stock worth $107,061,956. Corporate insiders own 31.30% of the company’s stock.
Hedge funds have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. lifted its holdings in Genomic Health by 166.0% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 790 shares of the medical research company’s stock valued at $55,000 after acquiring an additional 493 shares during the period. Manchester Capital Management LLC bought a new position in Genomic Health in the first quarter valued at about $56,000. Pearl River Capital LLC bought a new position in Genomic Health in the first quarter valued at about $70,000. C M Bidwell & Associates Ltd. bought a new position in Genomic Health in the first quarter valued at about $83,000. Finally, Royce & Associates LP lifted its holdings in Genomic Health by 22.8% in the fourth quarter. Royce & Associates LP now owns 1,473 shares of the medical research company’s stock valued at $95,000 after acquiring an additional 273 shares during the period. 91.80% of the stock is currently owned by institutional investors.
Shares of NASDAQ GHDX traded up $0.27 during trading on Monday, reaching $56.72. The company had a trading volume of 10,053 shares, compared to its average volume of 479,936. Genomic Health has a 12-month low of $36.94 and a 12-month high of $92.18. The stock has a market cap of $2.11 billion, a P/E ratio of 54.56 and a beta of 0.88. The company has a current ratio of 5.67, a quick ratio of 5.67 and a debt-to-equity ratio of 0.19.
Genomic Health (NASDAQ:GHDX) last released its earnings results on Tuesday, May 7th. The medical research company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.29 by $0.05. Genomic Health had a return on equity of 18.70% and a net margin of 10.35%. The firm had revenue of $108.80 million for the quarter, compared to analysts’ expectations of $106.75 million. During the same period in the prior year, the firm posted ($0.11) earnings per share. The company’s quarterly revenue was up 17.5% on a year-over-year basis. As a group, analysts forecast that Genomic Health will post 1.46 earnings per share for the current fiscal year.
Genomic Health Company Profile
Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.
Recommended Story: Marijuana Stocks
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.